On health effects of resveratrol in wine. A bibliometric view based on papers having achieved a high citation impact within the scientific discourse

2.1 Dataset

The topic of our research includes different disciplines (e.g., chemistry, medicine, biology, and life sciences). Therefore, we used the multidisciplinary database Web of Science (WoS; 8) for this study. In WoS, we used the following search query to find publications related to resveratrol (probably also its derivatives) and wine: TS=(Resveratrol* SAME (Wine* OR Vin* OR Grap* OR Vitis*)). By this we searched for “resveratrol” and the wine synonyms in the title, abstract, and keywords of publications. The operator SAME ensures that the term resveratrol and any of the wine synonyms is found in the same topic field (e.g., both terms occur in the title, or both terms occur in one of the other two topic fields).

We analyzed the WoS subject categories within the result set to find health-related ones. We used those health-related WoS subject categories to combine them with our search query related to resveratrol and wine for obtaining our final WoS query that is included in supporting information S1. We retrieved 3344 papers on October 05, 2021.

2.2 Methods

We created co-occurrence maps of author keywords using VOSviewer (9). The distance between two nodes is determined by the co-occurrence frequency of the terms. The size of the nodes is dependent on the number of publications with a specific keyword. The nodes can be colored according to various characteristics (e.g., cluster assignments, average number of citations, or average publication year). We colored the nodes according to the average publication years of the publications connected to them. We included author keywords if they occurred at least ten times.

We imported all 3344 papers with 181,218 cited references into CRExplorer (https://crexplorer.net; 10, 11, 12). The distinct number of cited references amounts to 94,828. Up to 30 different citing publication years are occurring. We used the automatic algorithm for clustering equivalent cited references with volume and page activated and a Levenshtein threshold of 0.75. This enabled merging of 165 cited references. We removed 92,771 cited references that occurred less than ten times to sharpen the spectrogram and avoid noise. Thus, 1892 cited references remained for our analysis. The RPYS spectrogram was plotted using R (13) with the R package ‘BibPlots’ (14). In addition to the static RPYS plot in this paper, we produced an interactive RPYS graph using the R package ‘dygraphs’ (15). We analyzed the RPYS spectrogram regarding relevant peaks of the five-year median deviation. Tukey’s fences (16) were used to support the identification of the most important peaks: Important peaks are flagged based on the interquartile range of the median deviations (17). If unflagged RPYs with a similar NCR value occur around flagged RPYs, those unflagged RPYs should also be investigated. In addition, cited references that were cited very frequently in many citing years (N_TOP10>=15) were analyzed (18). Such very frequently cited references might not form pronounced peaks in the spectrogram. Thus, the N_TOP10 indicator is important to consider for finding frequently cited references. We also investigated the 15 most-referenced cited references (referenced at least 200 times).

3.1 Annual publication profile

Figure 1 shows the annual publication profile of papers that deal with resveratrol in connection with wine and health. The number of publications is overall increasing until 2010 and slightly decreases afterwards.

• Download figure
• Open in new tab

Figure 1:

Annual publication profile of papers that deal with resveratrol in connection with wine and health

3.2 Keyword analysis

Figure 2 shows a semantic map of frequently occurring author keywords. Obvious synonyms (see Table S1 in supporting information S2) were grouped together. The nodes (i.e., keywords) are colored by the average publication year of the corresponding publications.

• Download figure
• Open in new tab

Figure 2:

Semantic map of author keywords; clear synonyms (see Table B1) were grouped together; an interactive version is available at: https://s.gwdg.de/Q2BKwg.

For an overview of the thematic content of the publications dealing with health effects of resveratrol in wine, we categorized the keywords as follows: (1) Keywords related to beverages containing resveratrol (e.g., studies that analyze the amount of resveratrol as a function of the wine variety, the geographical origin, and the vinification process). (2) Keywords related to specific chemical compounds, particularly to the biochemistry of polyphenols. (3) Keywords related to the possible prevention of specific diseases. (4) Keywords studying possible health effects of resveratrol in vitro or in vivo. (5) Keywords that are focused on the biochemical mechanism of a specific health effect, by which resveratrol possibly acts. We have assigned the keywords in Figure 2 to those topics and include a further category with unspecific or broader terms (each arranged in the order of occurrence):

1. Beverages related: wine (133), red wine (108), grapes (72), vitis vinifera (37), grape juice (22), grape seed extract (18), grapevine (13), vitis amurensis (12), vitaceae (12)

2. Compounds related: resveratrol (1531), polyphenols (306), stilbenes (90), nitric oxide (86), phenolics (57), flavonoids (56), reactive oxygen species (56), quercetin (54), alcohol (53), phytochemical (48), piceatannol (40), hplc (34), pterostilbene (34), curcumin (29), ethanol (26), egcg (21), cytokines (20), sirtuins (20), ampk (19), glutathione (16), phytoestrogen (15), red wine polyphenols (15), calcium (13), cytochrome p450 (13), stilbenoids (13), anthocyanins (12), caspase-3 (12), cholesterol (12), piceid (12), bcl-2 (11), catechin (11), cisplatin (11), cyclooxygenase (11), genistein (11), grape polyphenols (11), phytoalexin (11), superoxide dismutase (11), beta amyloid (10), doxorubicin (10), epsilon viniferin (10), hydrogen peroxide (10), lipopolysaccharide (10), melatonin (10), polydatin (10).polygonum cuspidatum (10)

3. Diseases related: atherosclerosis (63), cardiovascular disease (63), cancer (58), alzheimer’s disease (46), diabetes (34), obesity (32), breast cancer (28), colon cancer (26), hypertension (25), liver (25), prostate cancer (23), diet (18), blood pressure (17), colorectal cancer (15), ischemia (15), metastasis (15), brain (14), heart (14), parkinson’s disease (14), nf2 (13), hippocampus (12), ischemial/reperfusion (12), cardiovascular (11), cerebral ischemia (11), neuroinflammation (11), microglia (10), neurodegeneration (10), osteoblast (10)

4. Effects related: apoptosis (240), oxidative stress (201), antioxidant (189), inflammation (93), chemoprevention (68), neuroprotection (65), antioxidant activity (51), rats (41), cardioprotection (24), mediterranean diet (24), nutraceutical (23), anti-inflammatory (20), invasion (16), antioxidant capacity (13), prevention (13), cancer chemoprevention (12), clinical trials (12), health (12), anticancer (11), french paradox (11), neuroinflammation (11), high-fat diet (10), insulin resistance (10)

5. Mechanisms related: cell cycle (39), sirt1 (55), nf-kappa b (38), angiogenesis (33), cytotoxicity (33), mitochondria (32), bioavailability (31), autophagy (28), metabolism (27), pharmacokinetics (27), endothelium (26), free radicals (26), p53 (25), lipid peroxidation (24), endothelial cells (22), platelets (16), gene expression (15), molecular docking (15), endothelial function (14), platelet aggregation (14), tnf-alpha (14), dna damage (13), macrophages (12), vegf (12), blood platelets (11), caco-2 cells (10), endothelial dysfunction (10), estrogen receptor (10), inducible nitric oxide synthase (10)

6. Broader terms: aging (41), proliferation (28), akt (21), cell proliferation (20), longevity (12), migration (11), differentiation (10), natural products (10), ros (10), toxicity (10)

3.3 Reference analysis

Figure 3 shows the RPYS spectrogram of the wine- and health-related resveratrol research. The grey bars show the number of cited references (NCR) in each year, and the blue line shows the five-year median deviation. Outlier peaks are indicated by red stars and marked with their RPY.

• Download figure
• Open in new tab

Figure 3:

RPYS spectrogram of the wine- and health-related resveratrol research; an interactive version is available at: https://s.gwdg.de/i4qfNZ.

Table 1 shows the most frequently cited references below the main peaks in Figure 3. Although 1939/1940 is not an outlier peak, we included CR1 and CR2 from these two years because they report about the first isolation of phenolic substances from the roots of the medical plant white hellebore (Veratrum grandiflorum). These CRs can be seen as the historical origin of research on resveratrol as a plant product.

In CR3, Langcake and Pryce reported the detection of trans-resveratrol in vitis vinifera and other vitaceaes as a response to infection and injury. In CR4, Renaud and Delorgeril discussed the so-called French paradox for coronary heart-disease (CHD) in connection with the consumption of alcohol and particularly of red wine. Inhibition of platelet aggregation by wine rather than an effect on atherosclerosis is presented as an explanation for protection from CHD in France. In CR5, Siemann and Creasy reported that the concentration of resveratrol in selected wines was determined as a function of variety, geographical origin, growing methods, and winemaking procedures. The results indicated that resveratrol might be the active ingredient in wines causing reduction of serum lipids. In CR6 and CR7, Frankel et al. reported that besides the alcohol content of wine, the phenolic compounds in red wine are assumed to have an important role in connection with the French paradox. The in-vitro studies show that the antioxidant properties of the phenolic substances in red wine inhibit the copper-catalyzed oxidation of human LDL. In CR8, Fitzpatrick et al. investigated possible effects of various grape wines and other grape products on vascular function in vitro. They remarked that “[i]f such responses occur in vivo, they could … contribute to a reduced incidence of coronary heart disease” (19). In CR9, Pace-Asciak et al. identified trans-resveratrol to be most important for the inhibition of platelet aggregation, thereby explaining the protective role of red wine against atherosclerosis and CHD. In CR10, Bertelli et al. examined the antiplatelet activity of synthetic and natural resveratrol in red wine. The results show that the antiaggregating effect of resveratrol is related to its concentration in red wine. In CR11, Jang et al. reported that resveratrol was found to have cancer preventive activity by acting as an antioxidant and antimutagen. The data suggest that resveratrol merits investigations as a potential cancer chemopreventive agent in humans. In CR12, Gehm et al. presented a study that broadens the spectrum of the biological actions of phenolic compounds in grapes and wines. They examined the estrogenic actions of resveratrol as a phytoestrogen in connection with human breast cancer cells. In CR13, Soleas et al. reviewed the literature about resveratrol. The authors of this review miss conclusive evidence for the absorption of resveratrol by humans in biologically significant amounts. They question but do not exclude beneficial activities as a consequence of moderate red wine consumption.

In CR14, Fremont summarized the various biological effects of resveratrol isomers in connection with human cardiovascular diseases and cancer. It is suggested that the bioavailability and the metabolic pathways should be better known before drawing any conclusions on the benefits of resveratrol to health. In CR15, Manna et al. reported that the anti-cancerogenic and anti-inflammatory effects of resveratrol are partially ascribed by the inhibition of the activation of a nuclear transcription factor (NP-kappa B and AP-1) and associated kinases. In CR16, Hung et al. reported that resveratrol was found to be a potent antiarrhythmic agent with cardioprotective properties in rats, possibly correlated with its antioxidant activity and upregulation of NO production. In CR17, Wallerath et al. reported about the effect of resveratrol on nitric oxide synthase expression (eNOS) in human endothelial cells. In conclusion, the stimulation of eNOS expression may contribute to the cardiovascular protective effects attributed to resveratrol. In CR18, Burns et al. examined the concentrations of resveratrol and its glycoside in grapes, peanuts, and Itadori tea, “which has long been used in Japan and China as a traditional herbal remedy heart disease and stroke” (20). The authors state that “for people who do not consume alcohol, Itadori tea may be a suitable substitute for red wine” (20). In CR19, Wang et al. demonstrated for the first time, that resveratrol can cross the blood-brain barrier and exert protective effects against cerebral ischemic injury. In CR20, Baur and Sinclair comprehensively and critically reviewed in vivo data on resveratrol and considered its potential as a therapeutic for humans.

In CR21, Baur et al. discussed the improvement of health and survival of mice by resveratrol. The data “show that improving general health in mammals using small molecules is an attainable goal” (21). In CR22, Lagouge et al. revealed that resveratrol improves mitochondrial function and protects against metabolic disease in mice. In CR23, Brown et al. examined the cancer chemoprotective activity in healthy volunteers and analyzed the pharmacokinetic effects after repeated doses of resveratrol. “The results suggest that repeated administration of high doses of resveratrol generates micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma. The observed decrease in circulating IGF-I and IGFBP-3 might contribute to cancer chemopreventive activity.” (22) In CR24, Cottart et al. reviewed the results of recent studies that investigated the pharmacokinetics, bioavailability, and toxicity of resveratrol in humans. As a result, resveratrol seems to be well tolerated with no marked toxicity, which provides further support for the use as a pharmacological drug in human medicine. In CR25, Pacholec et al. analyzed activation of SIRT1 by resveratrol and other structurally related compounds. The authors concluded that the tested compounds are not direct activators of SIRT1. In CR26, Patel et al. presented their study about the clinical pharmacology of resveratrol in colorectal cancer patients. The results suggest that daily p.o. doses of resveratrol at 0.5 or 1.0 g elicit anticancerogenic effects. The authors stated that “resveratrol merits further clinical evaluation as a potential colorectal cancer chemopreventive agent” (23). In CR27, Chow et al. analyzed the effect of pharmacological doses of resveratrol on drug- and carcinogen-metabolizing enzymes of healthy volunteers. The authors concluded that resveratrol can modulate enzyme systems and thereby inhibit carcinogenesis. They suggest to consider lower doses of resveratrol for cancer prevention to minimize adverse metabolic drug interactions.

In CR28, Subbaramaiah et al. report about the inhibition of specific biochemical pathways in human mammary and oral epithelial cells. The authors state that their “data are likely to be important for understanding the anti-cancer and anti-inflammatory properties of resveratrol.” (24) In CR29, Howitz et al. found that resveratrol mimics caloric restriction of saccharomyces, resulting in increased DNA stability and extended lifespan of lower organisms. In CR30, Clement et al. reported on the anti-cancer activity of resveratrol by triggering the apoptosis in human tumor cells. The authors state that their data highlight the chemotherapeutic potential of resveratrol. In CR31, Goldberg et al. reported on the absorption of three wine-related polyphenols (trans-resveratrol, catechin, and quercetin) by healthy males, measuring the polyphenols in blood serum and urine after oral consumption. The absorption of trans-resveratrol was found to be the most efficient. In CR32, Walle et al. found high absorption but very low bioavailability of oral resveratrol in humans. However, they state that accumulation of resveratrol and its metabolites in epithelial cells may still cause cancer-preventive effects. In CR33, Aggarwal: et al. present an overview of preclinical and clinical studies dealing with the role of resveratrol in the prevention and therapy of cancer. In CR34, Ray et al. studied the potential cardioprotective effects of resveratrol using isolated rat hearts. The results indicate “that resveratrol possesses cardioprotective effects which may be attributed to its peroxyl radical scavenging activity.” (25) In CR35, Bowers et al. reported on the biochemistry of resveratrol in connection with estrogen receptors, which seem to be important for the health effects of polyphenols. In CR36, Wu et al. reviewed the literature concerning the biosynthesis and presence of resveratrol in food groups and wines, the various reported health effects of resveratrol, and particularly the mechanism of its cardio-protective effect.

No additional cited references were found within the 15 most referenced cited references (NCR>=200). Therefore, we assume that we found the most impactful studies that are listed in Table 1 and Table 2.